Laurence Greenhill is a Depression (MDD) physician affiliated with New York State Psychiatric Institute. OpenAlex indexes 286 publications with 36,864 citations (h-index 91); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Child & Adolescent Psychiatry profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Laurence Greenhill, MD, is affiliated with New York State Psychiatric Institute. The public record shows 286 publications with 36,864 citations (h-index 91), centered on Depression (MDD). It also documents an investigator role on 7 registered clinical trials, 11 NIH-funded awards (1985–2011).
- Top research focus: Depression (MDD)
- 7 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
Sponsor: Rhodes Pharmaceuticals, L.P.
- Treatment of Children With ADHD Who do Not Fully Respond to Stimulants
Sponsor: New York State Psychiatric Institute
- Long-Duration Stimulant Treatment Study of ADHD in Young Children
Sponsor: New York State Psychiatric Institute
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
92.8%Benzodiazepine36.1%Lorazepam46%Alprazolam23%Clonazepam19%Temazepam12%Part D<11 patientsSSRI35%Fluoxetine Hcl29%Trazodone Hcl23%Escitalopram Oxalate23%Sertraline Hcl18%Paroxetine Hcl8%Part D<11 patientsCardiovascular
4.1%Beta blocker4.1%Propranolol Hcl100%Part D<11 patientsMusculoskeletal
3.1%Central alpha-2 Adrenergic Agonist3.1%Tizanidine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
11 NIH research awards on record, funded 1985–2011 per NIH RePORTER. The latest:
- FOLLOW-UP OF THE MULTIMODAL TREATMENT STUDY OF CHILDREN WITH ATTENTION DEFICIT H
Research Foundation for Mental Hygiene
FY2011$450,364271200800007C - Funding for MTA study (NIMH) - Columbia
Research Foundation for Mental Hygiene
FY2010$210,192271200800007C - FOLLOW-UP OF THE MULTIMODAL TREATMENT STUDY OF CHILDREN WITH ATTENTION DEFICIT H
Research Foundation for Mental Hygiene
FY2009$426,802271200800007C
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Young adult outcomes in the follow‐up of the multimodal treatment study of attention‐deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression
Journal of Child Psychology and Psychiatry
2017 - Functional Adult Outcomes 16 Years After Childhood Diagnosis of Attention-Deficit/Hyperactivity Disorder: MTA Results
Journal of the American Academy of Child & Adolescent Psychiatry
2016 - Adolescent Substance Use in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder (ADHD) (MTA) as a Function of Childhood ADHD, Random Assignment to Childhood Treatments, and Subsequent Medication
Journal of the American Academy of Child & Adolescent Psychiatry
2013 - The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-Year Follow-Up
Journal of the American Academy of Child & Adolescent Psychiatry
2013
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/laurence-greenhill-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
thereachinstitute.org/new-treatments-for-adhd
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →thereachinstitute.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care